Epsilon-V1-2 (20 mg/kg/day; osmotic pumps; daily; for 4 weeks) treatment significantly improves the beating score in a murine heterotopic transplantation model. Epsilon-V1-2 reduces infiltration of macrophages and T cells into the cardiac grafts, and decreases parenchymal fibrosis. Epsilon-V1-2 treatment almost abolishes the rise in pro-fibrotic cytokine, TGF-β and monocyte recruiting chemokine MCP-1 levels[3].
| Animal Model: | C57BL/6J mice transplanted the hearts of FVB mice[3] |
| Dosage: | 20 mg/kg/day |
| Administration: | 0.1 mL osmotic pumps implanted subcutaneously; daily; for 4 weeks |
| Result: | Significantly improved the beating score throughout the treatment.
|
